United States· US:63010-010_4af6d4ca-b410-48e3-925e-ce23a14db18a
VIRACEPT
A nelfinavir product containing nelfinavir mesylate, registered in United States by AGOURON. The same ATC class is registered in 3 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Nelfinavir is registered in 3 of 19 countries.
Countries holding a registration under ATC J05AE04 (nelfinavir), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 2 of them publish a price we can compare per daily dose
Nelfinavir · ATC J05AE04
3 / 19 countries
- Finlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- NELFINAVIR MESYLATE
- Manufacturer
- AGOURON
- Country
- United States (US)
- ATC code
- J05AE04
- ATC class
- Nelfinavir
- Defined daily dose
- 2.25 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1163010-010-30
- ndc116301001030300 TABLET, FILM COATED in 1 BOTTLE (63010-010-30)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
363 interactions on record for nelfinavir.
Graded by severity as the source publishes them — 135 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nelfinavir · interactions on record
363 records
- 135 severe
- 195 moderate
- 15 minor
- 15 info
Most severe, free to view
- OmeprazoleA02BC01severe
- PantoprazoleA02BC02severe
- LansoprazoleA02BC03severe
- RabeprazoleA02BC04severe
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nelfinavir in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/28f3a531-5d0f-4951-8299-ee6dcaf38a4e GET /v1/drugs/28f3a531-5d0f-4951-8299-ee6dcaf38a4e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "250",
"substance": "NELFINAVIR MESYLATE",
"productndc": "63010-010",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA020779",
"marketing_category": "NDA"
}See everything about nelfinavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.